Though the mechanism of tumor-cell specificity remains to be conclusively illustrated, tumor cell killing activity and tumor cell targeting specificity make DZ-CIS a promising agent for the clinical treatment of RCC, since DZ-CIS-mediated subcellular targeted cancer therapy can circumvent RCC’s therapeutic resistance. Here, CISH is linked to in situ carcinoma.